Literature DB >> 23313783

Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.

Oliver B Villaflores1, Chein-Ming Hsei, Chao-Yi Teng, Ying-Ju Chen, Jiunn-Jye Wey, Pei-Yi Tsui, Rong-Hwa Shyu, Kuo-Lun Tung, Jui-Ming Yeh, Der-Jiang Chiao, Tzong-Yuan Wu.   

Abstract

Clostridial botulinum neurotoxin (BoNT) is one of the most toxic proteins causing the food borne disease, botulism. In previous studies, recombinant BoNT production by Escherichia coli and yeast Pichia pastoris has been hampered by high AT content and codon bias in the gene encoding BoNT and required a synthetic gene to resolve this intrinsic bottleneck. This paper reports the simultaneous expression of the C-terminal heavy chain domain of BoNT (rBoNT/A-HC-6h) and enhanced green fluorescent protein (EGFP) using a bi-cistronic baculovirus-insect cell expression system. The expression of EGFP facilitated the monitoring of viral infection, virus titer determination, and isolation of the recombinant virus. Protein fusion with hexa-His-tag and one-step immobilized metal-ion affinity chromatography (IMAC) purification produced a homogenous, stable, and immunologically active 55-kDa rBoNT/A-HC-6h (about 3mg/L) with >90% purity. Furthermore, measured levels of serum titers were 8-folds for mice vaccinated with the purified rBoNT/A-HC-6h (2μg) than for mice administered with botulinum toxoid after initial immunization. Challenge experiment with botulinum A toxin demonstrated the immunoprotective activity of purified rBoNT/A-HC-6h providing the mice full protection against 10(2) LD50 botulinum A toxin with a dose as low as 0.2μg. This study provided supportive evidence for the use of a bi-cistronic baculovirus-Sf21 insect cell expression system in the facile expression of an immunogenically active rBoNT/A-HC.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313783     DOI: 10.1016/j.jviromet.2012.11.035

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  6 in total

1.  High-level expression and characterization of bioactive human truncated variant of hepatocyte growth factor in Escherichia coli.

Authors:  Xiaohua Wang; Haifeng Liu; Zhongmin Zhang; Yang Liu; Yuting Li; Jinqiu Gui; Yanhui Chu
Journal:  World J Microbiol Biotechnol       Date:  2014-08-14       Impact factor: 3.312

2.  Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Authors:  YunZhou Yu; DanYang Shi; Si Liu; Zheng-Wei Gong; Shuang Wang; ZhiWei Sun
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and E.

Authors:  Aurore Burgain; Alice Rochard; Capucine Trollet; Christelle Mazuet; Michel R Popoff; Virginie Escriou; Daniel Scherman; Pascal Bigey
Journal:  Hum Vaccin Immunother       Date:  2013-07-22       Impact factor: 3.452

4.  Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.

Authors:  Andrew W Hudacek; Fetweh H Al-Saleem; Mallory Willet; Travis Eisemann; Jeffrey A Mattis; Lance L Simpson; Matthias J Schnell
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-01       Impact factor: 6.698

5.  Expression and serological application of recombinant epitope-repeat protein carrying an immunodominant epitope of Newcastle disease virus nucleoprotein.

Authors:  Satish S Gaikwad; Hyun-Jeong Lee; Ji-Ye Kim; Kang-Seuk Choi
Journal:  Clin Exp Vaccine Res       Date:  2019-01-31

Review 6.  The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.

Authors:  Rachael S Felberbaum
Journal:  Biotechnol J       Date:  2015-03-20       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.